Pages that link to "Q48071920"

The following pages link to Highly attenuated HIV type 2 recombinant poxviruses, but not HIV-2 recombinant Salmonella vaccines, induce long-lasting protection in rhesus macaques (Q48071920):

Displaying 37 items.

• Nonhuman primate models for HIV/AIDS vaccine development (Q26861148) (← links)
• Induction of intestinal immunity by mucosal vaccines as a means of controlling HIV infection (Q27001897) (← links)
• Synthetic DNA vaccine strategies against persistent viral infections (Q27016078) (← links)
• Antibodies with high avidity to the gp120 envelope protein in protection from simian immunodeficiency virus SIV(mac251) acquisition in an immunization regimen that mimics the RV-144 Thai trial (Q30532861) (← links)
• Recombinant vaccine-induced protection against the highly pathogenic simian immunodeficiency virus SIV(mac251): dependence on route of challenge exposure. (Q33782797) (← links)
• Immunization with a modified vaccinia virus expressing simian immunodeficiency virus (SIV) Gag-Pol primes for an anamnestic Gag-specific cytotoxic T-lymphocyte response and is associated with reduction of viremia after SIV challenge (Q33799497) (← links)
• Recent advances with recombinant bacterial vaccine vectors. (Q33826608) (← links)
• Immunogenicity and protective efficacy of recombinant human T-cell leukemia/lymphoma virus type 1 NYVAC and naked DNA vaccine candidates in squirrel monkeys (Saimiri sciureus). (Q33842383) (← links)
• Vaccination with a Shigella DNA vaccine vector induces antigen-specific CD8(+) T cells and antiviral protective immunity (Q33846454) (← links)
• Recombinant vaccinia viruses. Design, generation, and isolation (Q33996980) (← links)
• Simian immunodeficiency virus infection of monkeys as a model system for the study of AIDS pathogenesis, treatment, and prevention (Q34050736) (← links)
• Partially assembled K99 fimbriae are required for protection (Q34111838) (← links)
• A combination DNA and attenuated simian immunodeficiency virus vaccine strategy provides enhanced protection from simian/human immunodeficiency virus-induced disease (Q34228507) (← links)
• Potent and broadly reactive HIV-2 neutralizing antibodies elicited by a vaccinia virus vector prime-C2V3C3 polypeptide boost immunization strategy (Q34290973) (← links)
• ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency (Q34326613) (← links)
• Applications of pox virus vectors to vaccination: an update (Q34403246) (← links)
• Mucosal priming of simian immunodeficiency virus-specific cytotoxic T-lymphocyte responses in rhesus macaques by the Salmonella type III secretion antigen delivery system (Q34471356) (← links)
• Systemic immunization with an ALVAC-HIV-1/protein boost vaccine strategy protects rhesus macaques from CD4+ T-cell loss and reduces both systemic and mucosal simian-human immunodeficiency virus SHIVKU2 RNA levels (Q34546037) (← links)
• HIV-1 vaccines: the search continues (Q34876150) (← links)
• Antibody to the gp120 V1/V2 loops and CD4+ and CD8+ T cell responses in protection from SIVmac251 vaginal acquisition and persistent viremia (Q35105449) (← links)
• Live, attenuated simian immunodeficiency virus vaccines elicit potent resistance against a challenge with a human immunodeficiency virus type 1 chimeric virus (Q35897786) (← links)
• Human immunodeficiency virus type 1 vaccine development: recent advances in the cytotoxic T-lymphocyte platform "spotty business". (Q36498186) (← links)
• Protection afforded by an HIV vaccine candidate in macaques depends on the dose of SIVmac251 at challenge exposure (Q36667917) (← links)
• Evaluation of recombinant influenza virus-simian immunodeficiency virus vaccines in macaques (Q37256687) (← links)
• Phase III HIV vaccine trial in Thailand: a step toward a protective vaccine for HIV (Q37785947) (← links)
• Canarypox virus-induced maturation of dendritic cells is mediated by apoptotic cell death and tumor necrosis factor alpha secretion (Q39597953) (← links)
• HIV/AIDS Vaccine Development: Challenges, Progress and Future Directions (Q40927003) (← links)
• Recombinant viruses as vaccines and immunological tools (Q41587132) (← links)
• Cytotoxic T-lymphocyte responses to canarypox vector-based HIV vaccines in HIV-seronegative individuals: a meta-analysis of published studies (Q44647967) (← links)
• Induction of Mucosal and Systemic Responses against Human Immunodeficiency Virus Type 1 Glycoprotein 120 in Mice after Oral Immunization with a Single Dose of aSalmonella-HIV Vector (Q45760357) (← links)
• Mucosal and systemic HIV-1 Env-specific CD8(+) T-cells develop after intragastric vaccination with a Salmonella Env DNA vaccine vector (Q50112634) (← links)
• Recombinant, attenuated Salmonella typhimurium stimulate lymphoproliferative responses to SIV capsid antigen in rhesus macaques. (Q50127295) (← links)
• Viremia control following antiretroviral treatment and therapeutic immunizationduring primary SIV251 infection of macaques (Q57089576) (← links)
• Didanosine but Not High Doses of Hydroxyurea Rescue Pigtail Macaque from a Lethal Dose of SIVsmmpbj14 (Q73664058) (← links)
• Viral Vectors for the Induction of Broadly Neutralizing Antibodies against HIV (Q90226623) (← links)
• Engagement of monocytes, NK cells, and CD4+ Th1 cells by ALVAC-SIV vaccination results in a decreased risk of SIVmac251 vaginal acquisition (Q90263714) (← links)
• Mucosal Vaccine Approaches for Prevention of HIV and SIV Transmission (Q92889493) (← links)